FindTrial
Sign In

EUCLID

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222014
Enrollment
Unknown
Registered
2013-01-30
Start date
2013-01-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Artery Disease

Interventions

investigational material(s) Generic name etc : Ticagrelor INN of investigational material : Ticagrelor Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Admini

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Symptomatic peripheral artery disease

Exclusion criteria

Exclusion criteria: - Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation - Patients with known bleeding disorders - Patients with a history of intracranial bleed - Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026